The main objective of the Science Advisory Board is to help people with mesothelioma. Constituted of world-renowned mesothelioma experts, the Board strives to ensure that the best mesothelioma and asbestos research projects from around the globe get funded, and that the scientific discoveries being made are quickly translated to clinical trials for early diagnosis and treatment.
Among those on our board of mesothelioma and asbestos research experts is Dr. Anne Tsao.
Meet Anne Tsao, MD
Dr. Anne S. Tsao is an Associate Professor in the Department of Thoracic/Head & Neck Medical Oncology at the University of Texas M.D. Anderson Cancer Center. She is the Director of the Mesothelioma Program and the Director of the Thoracic Chemo-Radiation Program at MDACC.
Dr. Tsao is a clinician scientist and an expert in the treatment of patients with both thoracic and head and neck cancers, with a specialization in mesothelioma. She conducts both clinical and translational laboratory research and is focused on identifying new therapeutic targets and developing novel strategies for the treatment of aerodigestive cancers and mesothelioma. Her research is focused on individualizing cancer therapy through understanding the molecular mechanisms of disease. Her laboratory research efforts have recently identified Src kinase as a new target for therapy (Molecular Cancer Therapeutics) and have also shown that N-cadherin is upregulated in mesothelioma (AACR 2008, ASCO 2008).
Dr. Tsao is the principle investigator of several active clinical trials at M.D. Anderson Cancer Center and is the national PI for SWOG 0905, a front-line trial of cisplatin-pemetrexed +/- cediranib in mesothelioma patients. She has been extremely successful with numerous awards and publications. She has received an ASCO Merit Award, M.D. Anderson Achievement in Research Award, ASCO Young Investigator Award, ASCO Career Development Award, NIH Clinician Scientist K12 Award, and Head and Neck SPORE Career Development Award. She serves as Program Project Leader on several large grants, including the Department of Defense PROSPECT grant. She has several first author publications in Journal of Clinical Oncology, CA Cancer, Cancer Epidemiology, Biomarkers & Prevention (CEBP), Journal of Thoracic Oncology, Cancer, Nature Medicine Clinical Oncology and Molecular Cancer Therapeutics. Dr. Tsao serves on the SWOG Mesothelioma Steering Committee, SWOG Lung Executive Committee, RTOG Lung Executive Committee, and is on the Scientific Board of the American Radium Society. She lectures on both a national and international level on novel therapies in the aerodigestive malignancies.